ARC: a framework for access, reciprocity and conduct in psychedelic therapies

Authors Meg J. Spriggs, Ashleigh Murphy-Beiner, Roberta Murphy, Julia Bornemann, Hannah Thurgur and Anne K. Schlag. Published May 11, 2023 Abstract The field of psychedelic assisted therapy (PAT) is growing at an unprecedented pace. The immense pressures this places on those working in this burgeoning field have already begun to raise important questions about risk  …


Cannabinoids and the endocannabinoid system in fibromyalgia: a review of preclinical and clinical research

Authors Stephanie Bourke, Anne Schlag, Saoirse Elizabeth O’Sullivan, David Nutt, David Finn Published May 21, 2022 Fibromyalgia affects millions of people worldwide and has a significant impact on quality of life. Fibromyalgia symptoms include persistent widespread pain, fatigue, stiffness, sleep disturbances and cognitive dysfunction. Endogenous cannabinoids (endocannabinoids), the body’s own marijuana-like transmitters, are involved in  …


Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21

Authors Anne Katrin Schlag, Michael Lynskey, Alan Fayaz, Alkyoni Athanasiou-Fragkouli, Brigitta Brandner, Barbara Haja, Elizabeth Iveson and David J. Nutt Published June 14, 2022 Medical Cannabis for Chronic Pain Chronic pain is a pervasive, and potentially disabling condition. In the UK it is estimated to affect between one third and one half of the adult  …


Are psychedelics dangerous? - What the research says

Authors Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill, David J Nutt Published February 3, 2022 Psychedelic medicines are a rapidly developing area of clinical research and public health policy. Despite an increasing body of studies highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue  …


Why doctors have a moral imperative to prescribe and support medical cannabis—an essay by David Nutt

Authors David J Nutt Published January 26, 2022 “Medical cannabis has been legal to prescribe since 2018—yet just a handful of prescriptions have been made in three years. The reasons: stigma, fear, and an entrenched resistance in the medical profession that is harming patients” Prof David Nutt – Founder of Drug Science The field of  …


Is LSD Safe - Latest Research Findings

Is LSD Safe? LSD, technically named lysergic acid diethylamide and also known as acid, is one of the most widely used psychedelic drugs. As it changes both your cognition and your perception, it’s natural to assume this comes with an element of risk and yet LSD is widely regarded to be very safe. But is  …


Controversies in Medical Cannabis

Knowledge about the therapeutic potential of medical cannabis has greatly improved over the past decade, with an ever-increasing range of developments in human clinical applications. A growing body of scientific evidence supports the use of medical cannabis products for some therapeutic indications, but for others, the evidence base remains disputed. One reason for this is  …


Drug Checking – The Evidence is Building!

The Loop, a non-profit NGO, introduced event-based drug checking in the UK in 2016 and community-based drug checking in 2018. The most recent findings from the Loop, published today, dig deeper into behavioural outcomes and ask what happens next, after people have used a drug checking service?

The study compares 10 key (positive, negative and neutral) outcomes of The Loop’s service that reached nearly 3,500 festival-goers in 2017, with a follow-up survey with a sub-sample three months later, to find out how the combination of test results and personalised health consultations affected their subsequent drug taking and risk management strategies.


Psychedelic Microdosing - Just a Placebo Effect?

Authors: Balázs Szigeti, Laura Kartner, Allan Blemings, Fernando Rosas, Amanda Feilding, David J. Nutt, Robin L. Carhart-Harris, David Erritzoe Published: March 2, 2021 What is microdosing? Psychedelic microdosing involves consuming psychedelics such as LSD or psilocybin mushrooms at a microdose, which is typically about 10% of a recreational dose. Microdosing is gaining increasing popularity, with  …

Multi Criteria Decision Analysis for Evaluating Government Policy Responses to Heroin Use

Authors: Steve Rolles, Anne Katrin Schlag, Fiona Measham, Lawrence Phillips, David Nutt, Daniel Bergsvik, Ole Rogeberg Published: February 25, 2021 This Drug Science research was published in the International Journal of Drug Policy. A further write-up was featured in the Academic Times. Globally, non-medical heroin use is generating significant public health and social harms, and  …

Medical cannabis dependence: A critical review of issues and evidence

Authors: Anne K Schlag, Chandni Hindocha, Rayyan Zafar, David J Nutt, H Valerie Curran Published: February 17, 2021 This Drug Science research was published in the Journal of Psychopharmacology. For recreational users, the estimated chances of becoming dependent on cannabis after any lifetime exposure is 8.9%, which is considerably lower than for cocaine (20.9%), alcohol  …

So near yet so far: why won’t the UK prescribe medical cannabis?

Authors: David Nutt, Steve Bazire, Lawrence D Phillips, Anne Katrin Schlag Published: September 21, 2020 This Drug Science research was published in the British Medical Journal Open, you can download the full report here. In November 2018 when the UK made cannabis-based products for medicinal use (CBPMs) legal most people assumed these would immediately be  …

Medical cannabis in the UK: From principle to practice

Authors: Anne Katrin Schlag, David S Baldwin, Michael Barnes, Steve Bazire, Rachel Coathup, H Valerie Curran, Rupert McShane, Lawrence D Phillips, Ilina Singh, David J Nutt Published: June 10, 2020 Read the full paper here (open access) Drug Science submits it's finding concerning the UK Medical cannabis industry. In our recent peer-reviewed publication, Drug Science  …

Prescribed CBD could help people quit cannabis

Authors: Tom P Freeman, Chandni Hindocha, Gianluca Baio, Natacha D C Shaban, Emily M Thomas, Danica Astbury, Abigail M Freeman, Rachel Lees, Sam Craft, Paul D Morrison, Michael A P Bloomfield, Dominic O'Ryan, Jane Kinghorn, Celia J A Morgan, Ali Mofeez, H Valerie Curran Published: July 28, 2020 A benchmark clinical trial published today shows  …

First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Authors: Ben Sessa, Chloe Sakal, Steve O’Brien and David Nutt Published: July 15, 2019 Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol  …

A multi-criterion decision analysis applied to alcohol and cannabis regulation

Authors: Ole Rogeberg, Daniel Bergsvik, Lawrence D. Phillips, Jan van Amsterdam, Niamh Eastwood, Graeme Henderson, Micheal Lynskey, Fiona Measham, Rhys Ponton, Steve Rolles, Anne Katrin Schlag, Polly Taylor, and David Nutt Published: February 17, 2018 In collaboration with drug experts in Norway and the UK, multi-criteria decision analysis has been applied to evaluating drug policies  …

Ketamine treatment for depression

A review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The review concludes that further restrictions around ketamine are not neccesary and provides a set of recomendations for oversight bodies that would support safe, effective, and ethical use. Read it here

Ketamine as an essential medicine

Authors: Polly Taylor, David Nutt, Val Curran, Rudi Fortson, and Graeme Henderson Published: March 11, 2016 A letter to The Lancet endorsing the WHO Expert Committee on Drug Dependence's conclusion that concerns over recreational ketamine abuse in no way outweigh ketamine's role as a life-saving anasthetic and essential medicine. For open-access to the full report  …

Drug Science ketamine review

Authors: Celia J.  A. Morgan and H. Valerie Curran Published: July 21, 2011 The first comprehensive review of the drug since its classification, DrugScience's ketamine review highlighted harms such as neurological and bladder damage. For open-access to the full report of this research, see below: Access full publication

MCDA Comparison of Drug and Alcohol Harms in the UK

Authors: David J Nutt, Leslie A King, and Lawrence D Phillips Published: November 1, 2010 An assessment of the various harms of drugs used recreationally in the UK using multi-criteria decision analysis (MCDA) – a method that uses relevant experts’ knowledge and experience to assess the actual and relative harms - download the paper here.  …